Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) CFO Sells $113,890.00 in Stock

Share on StockTwits

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) CFO Matthew P. Young sold 700 shares of the business’s stock in a transaction on Monday, September 17th. The shares were sold at an average price of $162.70, for a total transaction of $113,890.00. Following the sale, the chief financial officer now directly owns 33,468 shares of the company’s stock, valued at $5,445,243.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

JAZZ traded up $3.44 on Friday, hitting $158.82. 768,222 shares of the company’s stock were exchanged, compared to its average volume of 481,001. The firm has a market cap of $10.16 billion, a price-to-earnings ratio of 16.61, a price-to-earnings-growth ratio of 0.92 and a beta of 1.04. Jazz Pharmaceuticals PLC has a twelve month low of $128.58 and a twelve month high of $184.00. The company has a quick ratio of 3.62, a current ratio of 3.76 and a debt-to-equity ratio of 0.54.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Tuesday, August 7th. The specialty pharmaceutical company reported $3.49 earnings per share for the quarter, topping the consensus estimate of $3.23 by $0.26. The firm had revenue of $500.48 million for the quarter, compared to analyst estimates of $469.85 million. Jazz Pharmaceuticals had a net margin of 24.20% and a return on equity of 25.47%. Research analysts anticipate that Jazz Pharmaceuticals PLC will post 11.7 earnings per share for the current year.

Large investors have recently made changes to their positions in the business. Summit Trail Advisors LLC increased its stake in shares of Jazz Pharmaceuticals by 8,591.5% in the first quarter. Summit Trail Advisors LLC now owns 102,125 shares of the specialty pharmaceutical company’s stock valued at $102,000 after purchasing an additional 100,950 shares during the period. Financial Gravity Wealth Inc. acquired a new stake in shares of Jazz Pharmaceuticals in the first quarter valued at approximately $192,000. Tiverton Asset Management LLC acquired a new stake in shares of Jazz Pharmaceuticals in the second quarter valued at approximately $198,000. Moloney Securities Asset Management LLC acquired a new stake in shares of Jazz Pharmaceuticals in the second quarter valued at approximately $204,000. Finally, FDx Advisors Inc. acquired a new stake in shares of Jazz Pharmaceuticals in the second quarter valued at approximately $244,000. Institutional investors own 92.52% of the company’s stock.

JAZZ has been the subject of a number of research reports. BMO Capital Markets upped their price target on shares of Jazz Pharmaceuticals from $201.00 to $206.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 8th. Wells Fargo & Co reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals in a research report on Sunday, July 8th. BidaskClub cut shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, August 18th. Citigroup upped their price target on shares of Jazz Pharmaceuticals from $162.00 to $205.00 and gave the stock a “buy” rating in a research report on Tuesday, July 10th. Finally, Morgan Stanley cut shares of Jazz Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $183.00 price objective for the company. in a research report on Wednesday, July 11th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and sixteen have issued a buy rating to the company’s stock. Jazz Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $192.11.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Featured Article: Diversification in Your Portfolio

Insider Buying and Selling by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.